{
    "info": {
        "nct_id": "NCT03776136",
        "official_title": "A Multicenter, Open-label, Phase 2 Trial to Assess the Efficacy and Safety of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Melanoma Previously Exposed to an Anti-PD-1/L1 Agent (LEAP-004)",
        "inclusion_criteria": "* Has histologically or cytologically confirmed melanoma\n* Has unresectable Stage III or Stage IV melanoma per American Joint Committee on Cancer (AJCC) staging system version 8 that is not amenable to local therapy\n* Has the presence of ≥1 measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 as confirmed by BICR.\n* Has progressed on treatment with an anti-PD-1/L1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies\n* Has submitted pre-trial imaging\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1\n* Has provided a baseline tumor biopsy\n* Has resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia). If participant received major surgery or radiation therapy of >30 Gray (Gy), they must have recovered from the toxicity and/or complications from the Intervention\n* Male participants must agree to use approved contraception during the treatment period and for at least 120 days after the last dose of study intervention and refrain from donating sperm during this period\n* Female participants are not pregnant and not breastfeeding, and are not a woman of childbearing potential (WOCBP) or are a WOCBP who agrees to follow contraceptive guidance during the treatment period and for at least 120 days after the last dose of study intervention\n* Has adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study treatment\n* Has a known additional malignancy that is progressing or requires active treatment\n* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Has ocular melanoma\n* Has known hypersensitivity to active substances or any of their excipients including previous clinically significant hypersensitivity reaction to treatment with another monoclonal antibody\n* Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs)\n* Has an active infection requiring systemic therapy\n* Has known history of Human Immunodeficiency Virus (HIV) or HIV 1/2 antibodies\n* Has known history of or is positive for hepatitis B (hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (HCV RNA qualitative] is detected)\n* Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease\n* Has a history of active tuberculosis (Bacillus tuberculosis)\n* Has presence of a gastrointestinal condition including malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib\n* Has had major surgery within 4 weeks prior to first dose of study interventions (adequate wound healing after major surgery must be assessed clinically, independent of time elapsed for eligibility)\n* Has a pre-existing Grade ≥3 gastrointestinal or non-gastrointestinal fistula\n* Has radiographic evidence of major blood vessel invasion/infiltration\n* Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug\n* Has clinically significant cardiovascular disease within 12 months from first dose of study drug, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability\n* Has received prior radiotherapy within 2 weeks of Cycle 1 Day 1 with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks prior to Cycle 1 Day 1\n* Has received a live vaccine within 30 days before the first dose of study treatment\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment\n* Has a history or has current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator\n* Has had an allogeneic tissue/solid organ transplant\n* Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Has resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia). If participant received major surgery or radiation therapy of >30 Gray (Gy), they must have recovered from the toxicity and/or complications from the Intervention",
            "criterions": [
                {
                    "exact_snippets": "resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia)",
                    "criterion": "toxic effects of most recent prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If participant received major surgery or radiation therapy of >30 Gray (Gy), they must have recovered from the toxicity and/or complications from the Intervention",
                    "criterion": "toxicity and/or complications from major surgery or radiation therapy (>30 Gy)",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has adequate organ function",
            "criterions": [
                {
                    "exact_snippets": "Has adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has progressed on treatment with an anti-PD-1/L1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies",
            "criterions": [
                {
                    "exact_snippets": "Has progressed on treatment with an anti-PD-1/L1 monoclonal antibody (mAb)",
                    "criterion": "progression on anti-PD-1/L1 monoclonal antibody treatment",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment_type",
                            "expected_value": [
                                "anti-PD-1 monoclonal antibody",
                                "anti-PD-L1 monoclonal antibody"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies",
                    "criterion": "anti-PD-1/L1 monoclonal antibody administration regimen",
                    "requirements": [
                        {
                            "requirement_type": "administration_regimen",
                            "expected_value": [
                                "monotherapy",
                                "combination with other checkpoint inhibitors",
                                "combination with other therapies"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has the presence of ≥1 measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 as confirmed by BICR.",
            "criterions": [
                {
                    "exact_snippets": "presence of ≥1 measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 as confirmed by BICR",
                    "criterion": "measurable lesion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "computed tomography (CT)",
                                "magnetic resonance imaging (MRI)"
                            ]
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST 1.1"
                        },
                        {
                            "requirement_type": "confirmation",
                            "expected_value": "BICR"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has unresectable Stage III or Stage IV melanoma per American Joint Committee on Cancer (AJCC) staging system version 8 that is not amenable to local therapy",
            "criterions": [
                {
                    "exact_snippets": "unresectable Stage III or Stage IV melanoma per American Joint Committee on Cancer (AJCC) staging system version 8",
                    "criterion": "melanoma stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "Stage III",
                                "Stage IV"
                            ]
                        },
                        {
                            "requirement_type": "resectability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "staging_system_version",
                            "expected_value": "AJCC version 8"
                        }
                    ]
                },
                {
                    "exact_snippets": "not amenable to local therapy",
                    "criterion": "amenability to local therapy",
                    "requirements": [
                        {
                            "requirement_type": "amenability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male participants must agree to use approved contraception during the treatment period and for at least 120 days after the last dose of study intervention and refrain from donating sperm during this period",
            "criterions": [
                {
                    "exact_snippets": "Male participants must agree to use approved contraception during the treatment period and for at least 120 days after the last dose of study intervention",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception type",
                            "expected_value": "approved"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 120,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "refrain from donating sperm during this period",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "refrain from donating",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 120,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has submitted pre-trial imaging",
            "criterions": [
                {
                    "exact_snippets": "Has submitted pre-trial imaging",
                    "criterion": "pre-trial imaging",
                    "requirements": [
                        {
                            "requirement_type": "submission",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has provided a baseline tumor biopsy",
            "criterions": [
                {
                    "exact_snippets": "Has provided a baseline tumor biopsy",
                    "criterion": "baseline tumor biopsy",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female participants are not pregnant and not breastfeeding, and are not a woman of childbearing potential (WOCBP) or are a WOCBP who agrees to follow contraceptive guidance during the treatment period and for at least 120 days after the last dose of study intervention",
            "criterions": [
                {
                    "exact_snippets": "Female participants are not pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not a woman of childbearing potential (WOCBP)",
                    "criterion": "woman of childbearing potential status",
                    "requirements": [
                        {
                            "requirement_type": "WOCBP",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "are a WOCBP who agrees to follow contraceptive guidance during the treatment period and for at least 120 days after the last dose of study intervention",
                    "criterion": "contraceptive use agreement",
                    "requirements": [
                        {
                            "requirement_type": "contraceptive guidance agreement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraceptive guidance duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 120,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has histologically or cytologically confirmed melanoma",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically confirmed melanoma",
                    "criterion": "melanoma",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1",
            "criterions": [
                {
                    "exact_snippets": "Has an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Has radiographic evidence of major blood vessel invasion/infiltration",
            "criterions": [
                {
                    "exact_snippets": "radiographic evidence of major blood vessel invasion/infiltration",
                    "criterion": "major blood vessel invasion/infiltration",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": "radiographic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Has a diagnosis of immunodeficiency",
                    "criterion": "immunodeficiency diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent)",
                    "criterion": "chronic systemic steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg daily of prednisone equivalent"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any other form of immunosuppressive therapy within 7 days before the first dose of study treatment",
                    "criterion": "immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 7 days before the first dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a history of active tuberculosis (Bacillus tuberculosis)",
            "criterions": [
                {
                    "exact_snippets": "Has a history of active tuberculosis (Bacillus tuberculosis)",
                    "criterion": "active tuberculosis history",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis",
            "criterions": [
                {
                    "exact_snippets": "known active central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "awareness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known history of Human Immunodeficiency Virus (HIV) or HIV 1/2 antibodies",
            "criterions": [
                {
                    "exact_snippets": "Has known history of Human Immunodeficiency Virus (HIV)",
                    "criterion": "Human Immunodeficiency Virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HIV 1/2 antibodies",
                    "criterion": "HIV 1/2 antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received prior radiotherapy within 2 weeks of Cycle 1 Day 1 with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks prior to Cycle 1 Day 1",
            "criterions": [
                {
                    "exact_snippets": "Has received prior radiotherapy within 2 weeks of Cycle 1 Day 1",
                    "criterion": "prior radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last radiotherapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks prior to Cycle 1 Day 1",
                    "criterion": "palliative radiotherapy to bone lesions",
                    "requirements": [
                        {
                            "requirement_type": "time since last palliative radiotherapy to bone lesions",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has ocular melanoma",
            "criterions": [
                {
                    "exact_snippets": "Has ocular melanoma",
                    "criterion": "ocular melanoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "clinically significant hemoptysis ... within 2 weeks prior to the first dose of study drug",
                    "criterion": "hemoptysis",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor bleeding within 2 weeks prior to the first dose of study drug",
                    "criterion": "tumor bleeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known hypersensitivity to active substances or any of their excipients including previous clinically significant hypersensitivity reaction to treatment with another monoclonal antibody",
            "criterions": [
                {
                    "exact_snippets": "Has known hypersensitivity to active substances",
                    "criterion": "hypersensitivity to active substances",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity to ... any of their excipients",
                    "criterion": "hypersensitivity to excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "previous clinically significant hypersensitivity reaction to treatment with another monoclonal antibody",
                    "criterion": "clinically significant hypersensitivity reaction to monoclonal antibody treatment",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has had major surgery within 4 weeks prior to first dose of study interventions (adequate wound healing after major surgery must be assessed clinically, independent of time elapsed for eligibility)",
            "criterions": [
                {
                    "exact_snippets": "Has had major surgery within 4 weeks prior to first dose of study interventions",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate wound healing after major surgery must be assessed clinically, independent of time elapsed for eligibility",
                    "criterion": "wound healing after major surgery",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment method",
                            "expected_value": "clinical"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Is currently participating in ... a study of an investigational agent",
                    "criterion": "participation in a study of an investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "current participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has participated in a study of an investigational agent",
                    "criterion": "participation in a study of an investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "prior participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has used an investigational device within 4 weeks prior to the first dose of study treatment",
                    "criterion": "use of an investigational device",
                    "requirements": [
                        {
                            "requirement_type": "use within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to first dose"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a known additional malignancy that is progressing or requires active treatment",
            "criterions": [
                {
                    "exact_snippets": "Has a known additional malignancy",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "is progressing",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requires active treatment",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "active treatment requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study",
            "criterions": [
                {
                    "exact_snippets": "Has a known psychiatric or substance abuse disorder",
                    "criterion": "psychiatric or substance abuse disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "would interfere with cooperation with the requirements of the study",
                    "criterion": "ability to cooperate with study requirements",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has presence of a gastrointestinal condition including malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib",
            "criterions": [
                {
                    "exact_snippets": "presence of a gastrointestinal condition including malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib",
                    "criterion": "gastrointestinal condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "malabsorption",
                    "criterion": "malabsorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "gastrointestinal anastomosis",
                    "criterion": "gastrointestinal anastomosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any other condition that might affect the absorption of lenvatinib",
                    "criterion": "condition affecting absorption of lenvatinib",
                    "requirements": [
                        {
                            "requirement_type": "effect on lenvatinib absorption",
                            "expected_value": "might affect"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has clinically significant cardiovascular disease within 12 months from first dose of study drug, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability",
            "criterions": [
                {
                    "exact_snippets": "clinically significant cardiovascular disease within 12 months from first dose of study drug",
                    "criterion": "clinically significant cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Association Class III or IV congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "NYHA_class",
                            "expected_value": [
                                "Class III",
                                "Class IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cerebral vascular accident",
                    "criterion": "cerebral vascular accident",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac arrhythmia associated with hemodynamic instability",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "associated_with_hemodynamic_instability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has had an allogeneic tissue/solid organ transplant",
            "criterions": [
                {
                    "exact_snippets": "Has had an allogeneic tissue/solid organ transplant",
                    "criterion": "allogeneic tissue/solid organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease",
            "criterions": [
                {
                    "exact_snippets": "history of (non-infectious) pneumonitis/interstitial lung disease that required steroids",
                    "criterion": "(non-infectious) pneumonitis/interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "required steroids"
                        }
                    ]
                },
                {
                    "exact_snippets": "current pneumonitis/interstitial lung disease",
                    "criterion": "pneumonitis/interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "current presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received a live vaccine within 30 days before the first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Has received a live vaccine within 30 days before the first dose of study treatment",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days before first dose of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a history or has current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator",
            "criterions": [
                {
                    "exact_snippets": "Has a history or has current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study",
                    "criterion": "condition, therapy, or laboratory abnormality that might confound the results of the study",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Has a history or has current evidence of any condition, therapy, or laboratory abnormality that might ... interfere with the participation for the full duration of the study",
                    "criterion": "condition, therapy, or laboratory abnormality that might interfere with participation for the full duration of the study",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Has a history or has current evidence of any condition, therapy, or laboratory abnormality that ... is not in the best interest of the participant to participate, in the opinion of the treating investigator",
                    "criterion": "condition, therapy, or laboratory abnormality that is not in the best interest of the participant to participate, in the opinion of the treating investigator",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a pre-existing Grade ≥3 gastrointestinal or non-gastrointestinal fistula",
            "criterions": [
                {
                    "exact_snippets": "pre-existing Grade ≥3 gastrointestinal ... fistula",
                    "criterion": "gastrointestinal fistula",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": ""
                            }
                        },
                        {
                            "requirement_type": "pre-existing",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pre-existing Grade ≥3 ... non-gastrointestinal fistula",
                    "criterion": "non-gastrointestinal fistula",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": ""
                            }
                        },
                        {
                            "requirement_type": "pre-existing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs)",
            "criterions": [
                {
                    "exact_snippets": "Has an active autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs)",
                    "criterion": "systemic treatment for autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "treatment_type",
                            "expected_value": [
                                "disease modifying agents",
                                "corticosteroids",
                                "immunosuppressive drugs"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an active infection requiring systemic therapy",
            "criterions": [
                {
                    "exact_snippets": "Has an active infection requiring systemic therapy",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": "systemic therapy"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Has known history of or is positive for hepatitis B (hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (HCV RNA qualitative] is detected)",
            "criterions": [
                {
                    "exact_snippets": "Has known history of ... hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B (hepatitis B surface antigen [HBsAg] reactive)",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "reactivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has known history of ... hepatitis C",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis C (HCV RNA qualitative] is detected",
                    "criterion": "hepatitis C virus RNA (HCV RNA)",
                    "requirements": [
                        {
                            "requirement_type": "detection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}